Clinical Research Directory
Browse clinical research sites, groups, and studies.
CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
Sponsor: RenJi Hospital
Summary
This is an ambispective, single-center study to evaluate the survival outcomes, adverse events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.
Official title: Survival Outcomes, Adverse Events and Predictive Biomarkers for CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer, an Ambispective Single-center Cohort Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
172
Start Date
2023-04-30
Completion Date
2028-12-30
Last Updated
2023-05-16
Healthy Volunteers
No
Conditions
Interventions
CDK4/6 inhibitor
CDK4/6 inhibitors
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China